Sunshine Biopharma, Inc
SEC CIK 1402328 · SFBM · last insider filing 2026-04-14
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Natan David | Director | filed 2022 - 2026 |
| Slilaty Steve N. | Director · Chief Executive Officer | filed 2009 - 2024 |
| Sebaaly Camille | Director · Secretary | filed 2009 - 2022 |
| Keller Andrew Mark | Director | filed 2022 - 2022 |
| Kiderchah Rabi | Director | filed 2021 - 2021 |
| Kish James Daniel | Director | filed 2021 - 2021 |
| Telsey Andrew I | Director | filed 2021 - 2021 |
| Merzouki Abderrazzak | Director · Chief Operating Officer | filed 2015 - 2021 |
| Di Turi Michele | Director · Chief Operating Officer | filed 2009 - 2015 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Roy Michel | Chief Commercial Officer | filed 2025 - 2025 |
| Beaudoin Marc | Chief Operating Officer | filed 2024 - 2024 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.